Do anti-DFS70 antibodies temper disease activity and progression in SLE?
- PMID: 33530817
- PMCID: PMC8020300
- DOI: 10.1177/0961203321990439
Do anti-DFS70 antibodies temper disease activity and progression in SLE?
Conflict of interest statement
Comment on
-
Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice.Lupus. 2021 Feb;30(2):320-324. doi: 10.1177/0961203320969976. Epub 2020 Nov 11. Lupus. 2021. PMID: 33175665
References
-
- Aljadeff G, Shemer A, Katz I, et al.. Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus 2021; 30: 320--324. - PubMed
-
- Mahler M, Andrade LE, Casiano CA, Malyavantham K, Fritzler MJ. Anti-DFS70 antibodies: an update on our current understanding and their clinical usefulness. Expert Rev Clin Immunol 2019; 15: 241–250. - PubMed
-
- Mahler M, Parker T, Peebles CL, et al.. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol 2012; 39: 2104–2110. - PubMed
-
- Choi MY, Clarke AE, St PY, et al.. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus 2017; 26: 1051–1059. - PubMed
-
- Infantino M, Carbone T, Manfredi M, et al.. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J 2019; 21: 509–511. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
